Abbott is a member of the private sector delegation to the Global Fund board; multiple sources have confirmed to KEI that in September 2012, Abbott approached senior staff of the Global Fund asserting that the Global Fund encouraged principal recipients to purchase generic lopinavir+ritonavir and thus"violate patents on its protease inhibitor Kaletra.